Latest Articles

Publication Date
All News Scientific
MAFS Australia 2025: Are Veronica and Eliot still together? - New Idea

MAFS Australia 2025: Are Veronica and Eliot still together? New Idea

Published: Feb. 18, 2025, 10 a.m.
Read Full Article
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).

Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other …

Published: Jan. 8, 2025, midnight
Read Full Article
Adverse event reporting system Depression Epidemiology Pharmacovigilance Progestogen
GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.

Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial …

Published: Dec. 31, 2024, midnight
Read Full Article
Abarelix Cetrorelix Degarelix Ganirelix GnRH peptide antagonists Teverelix assisted reproductive technologies prostate cancer
Recent Trends in Medical Management of Endometriosis.

Endometriosis affects about 10 percent women in the reproductive age group globally and approximately 42 million in India. Managing the patient's pain symptoms associated with endometriosis appears to be the …

Published: Dec. 26, 2024, midnight
Read Full Article
Dienogest Elagolix Endometriosis-associated pain Hormone therapy endometriosis Medical management of endometriosis Medical therapy endometriosis Oral GnRH antagonist
Healthy Ideas Awarded Funding Through NHMRC Program - Mirage News

Healthy Ideas Awarded Funding Through NHMRC Program Mirage News

Published: Dec. 17, 2024, 5:38 a.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - BioSpace

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer BioSpace

Published: Dec. 10, 2024, 12:23 p.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - Yahoo Finance

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer Yahoo Finance

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
Larger Waistline May Not Be Always Bad: Know Ideal Waist Size If You've Diabetes - Medical Daily

Larger Waistline May Not Be Always Bad: Know Ideal Waist Size If You've Diabetes Medical Daily

Published: Dec. 6, 2024, 7:47 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!